Journal of Comparative Effectiveness Research is a leading academic journal dedicated to the evaluation of healthcare interventions and practices, published by Becaris Publishing. Since transitioning to a fully Open Access model in 2023, the journal has expanded its accessibility to a global audience of researchers, healthcare professionals, and policy makers. With a focus on comparative effectiveness in health policy, it has achieved a notable ranking of #132 out of 310 in the Scopus category for Medicine and Health Policy, placing it in the 57th percentile for scholarly impact. Operating from the United Kingdom, the journal encompasses research from 2012 to 2024 and firmly establishes itself in the academic landscape as a Q2 journal in the Health Policy category as of 2023. By disseminating high-quality, evidence-based research, the Journal of Comparative Effectiveness Research plays a vital role in informing clinical practice and health policy decision-making, making it an essential resource for those dedicated to improving health outcomes.

Mayo Clinic Proceedings is a premier peer-reviewed medical journal published by Elsevier Science Inc, dedicated to advancing clinical practice through high-quality research, reviews, and case reports since its inception in 1945. With an impressive impact factor and recognized as a Q1 journal in the Medicine (miscellaneous) category, it ranks as #21 out of 636 in the realm of General Medicine, placing it in the top 96th percentile among its peers. The journal serves as a vital resource for healthcare professionals, researchers, and students by promoting evidence-based medicine that addresses contemporary challenges in clinical practice. Although it does not currently offer open access options, its rigorous publication standards ensure that its findings are credible and relevant, making it an essential platform for disseminating significant medical advancements. With a commitment to progress in healthcare, the Mayo Clinic Proceedings continues to shape the future of medicine for audiences across the globe.

AME Case Reports, published by AME PUBLISHING COMPANY, is a peer-reviewed open-access journal dedicated to the dissemination of high-quality clinical case reports across various medical disciplines. With an expanding focus on innovative medical practices and clinical experiences, this journal serves as an essential platform for healthcare professionals, researchers, and medical students to share significant findings and insights that contribute to evidence-based practices. Although specific metrics such as impact factors and H-index are not currently available, the journal's commitment to academic rigor and accessibility fosters an environment for scholarly exchange and professional development. The publication facilitates immediate access to important case studies that may inform clinical decisions and improve patient care. In an era where sharing specialized knowledge is paramount, AME Case Reports stands as a vital resource for those involved in the medical community worldwide.

The Electronic Journal of General Medicine is a distinguished open-access publication dedicated to advancing the field of general medicine through the dissemination of high-quality research and innovative practices. Published by MODESTUM LTD in the United Kingdom, this journal has been a pivotal platform for medical professionals and researchers since 2018, with an impressive Scopus ranking of #145 out of 636 in the Medicine category, placing it in the 77th percentile. It holds a Q3 quartile ranking in the 2023 medicine (miscellaneous) category, underscoring its relevance and contribution to the academic community. The journal focuses on a wide range of topics within general medicine, inviting original research articles, reviews, and case studies that address contemporary medical challenges. By providing a straightforward publication avenue, the Electronic Journal of General Medicine fosters knowledge exchange and stimulates scholarly dialogue, making it an essential resource for researchers, healthcare professionals, and students seeking to stay informed on the latest developments in the field.

Welcome to the Journal of Taibah University Medical Sciences, a distinguished open-access publication dedicated to advancing knowledge in the field of medicine. Since its inception in 2006, and published by ELSEVIER, this journal has become a vital resource for researchers and healthcare professionals alike, reflecting a steadfast commitment to disseminating innovative research and high-quality medical studies. With an impressive impact factor and a Scopus ranking placing it in the top 25% of general medicine journals, this publication occupies a notable position in the academic landscape. The journal covers a wide array of topics within the medical sciences, from clinical research to public health initiatives. As a Q3 category journal in the 2023 rankings, it continues to attract submissions that contribute meaningfully to the diverse and evolving field of medicine, supporting an open-access model that ensures widespread accessibility to its invaluable content. Explore the Journal of Taibah University Medical Sciences to stay abreast of the latest scientific advancements and engage with fellow scholars across the globe.

Psoriasis-Targets and Therapy is a leading open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the knowledge and understanding of psoriasis treatment and management. Launched in 2011, this journal provides a platform for high-quality research that encompasses clinical studies, therapeutic advances, and novel targeted therapies for psoriasis. With a focus on the latest findings and innovative approaches, Psoriasis-Targets and Therapy serves as an essential resource for researchers, healthcare professionals, and students seeking to stay at the forefront of this dynamic field. The journal's commitment to open-access publishing ensures that critical insights and breakthroughs are readily available to the global medical community, fostering collaboration and progress in psoriasis treatment strategies. Researchers are encouraged to submit their findings to contribute to the growing body of knowledge that will ultimately improve patient care and outcomes.

ANNALS ACADEMY OF MEDICINE SINGAPORE is a reputable journal dedicated to the field of medicine, published by the Academy of Medicine, Singapore. With an E-ISSN of 2972-4066, this journal has been an influential platform since its inception in 1973, aiming to disseminate high-quality research and clinical findings pertinent to both local and international audiences. Currently ranked in the Q3 quartile in Medicine (miscellaneous), it holds a commendable 83rd percentile in Scopus rankings, indicating its significant academic contribution within the competitive landscape of medical literature. Although the journal operates on a traditional subscription-based model, it continues to provide access to critical insights that serve not only researchers but also healthcare professionals and students engaged in the ever-evolving medical sector. As it approaches its comprehensive publication mark in 2024, ANNALS will continue to focus on enhancing global healthcare discourse, making it an invaluable resource for those committed to advancing medical knowledge and practice.

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

Journal of Health Economics and Outcomes Research, published by COLUMBIA DATA ANALYTICS, LLC, serves as a vital resource in the field of health policy and public health, providing researchers, professionals, and students with open access to pioneering studies since its inception in 2013. With its ISSN and E-ISSN both listed as 2327-2236, this journal aims to disseminate high-quality research that evaluates healthcare efficiency and outcomes. Situated in the United States, at 145 Hudson St., Suite 205, New York, NJ 10013, it has made significant strides in its category quartiles within the 2023 rankings, achieving Q2 status in both Health Policy and Public Health, Environmental and Occupational Health. Furthermore, it maintains respectable Scopus rankings, with a percentile of 51st in health policy and 49th in public health. By bridging gaps in health economics and policy discourse, the journal stands as an indispensable platform for advancing knowledge and fostering innovation in health services research.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.